Statistical Validation of Surrogate Endpoints: Problems and Proposals
- 1 April 2000
- journal article
- other
- Published by Springer Science and Business Media LLC in Drug Information Journal
- Vol. 34 (2), 447-454
- https://doi.org/10.1177/009286150003400213
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The Value of Surrogate Endpoints for Evaluation of Therapeutic EfficacyDrug Information Journal, 1998
- Surrogate Endpoints in Aids Drug Development: Current StatusDrug Information Journal, 1998
- Faster Access to Drugs for Serious or Life-Threatening Illnesses Through use of the Accelerated Approval Regulation in the United StatesDrug Information Journal, 1998
- Perspective: Validating Surrogate Markers--Are We Being Naive?The Journal of Infectious Diseases, 1997
- Evaluating the role of CD4‐lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trialsStatistics in Medicine, 1993
- Surrogate endpoints: A basis for a rational approachEuropean Journal of Clinical Pharmacology, 1992
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989
- Surrogate endpoints in clinical trials: CancerStatistics in Medicine, 1989
- Fieller's theorem vs. The delta method for significance intervals for ratiosJournal of Statistical Computation and Simulation, 1975